Combination of C-reactive protein and High Molecular Weight (HMW)-adiponectin reflects further metabolic abnormalities compared with each of them alone in Japanese type 2 diabetic subjects

Endocrine Journal

Volumn 55, Issue 2, 2008, Pages 331-338

  Saisho, Yoshifumi ^a   Hirose, Hiroshi ^a   Yamamoto, Yukihiro ^a   Nakatani, Hiroshi ^a   Itoh, Hiroshi ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Adiponectin; C reactive protein; Coronary risk factor; Type 2 diabetes mellitus

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; FEMALE; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HOMEOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; SYSTOLIC BLOOD PRESSURE; UNIVARIATE ANALYSIS;

ADIPONECTIN; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; JAPAN; MALE; MIDDLE AGED; OBESITY; PREDICTIVE VALUE OF TESTS; TRIGLYCERIDES;

EID: 43449104757     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K07E-032     Document Type: Article

References (43)

1. Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37: 1595-1607.
2. Ross R (1999) Atherosclerosis - an inflammatory disease. N Engl J Med 340: 115-126.
3. Kannel WB, McGee DL (1979) Diabetes and cardiovascular disease. The Framingham study. JAMA 241: 2035-2038.
4. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. (2000) Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 321: 199-204.
5. Chandran M, Phillips SA, Ciaraldi T, Henry RR (2003) Adiponectin: more than just another fat cell hormone? Diabetes Care 26: 2442-2450.
6. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB (1999) Elevated C-reactive protein levels in overweight and obese adults. JAMA 282: 2131-2135.
7. Ford ES (1999) Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care 22: 1971-1977.
8. Aronson D, Bartha P, Zinder O, Kerner A, Shitman E, Markiewicz W, et al. (2004) Association between fasting glucose and C-reactive protein in middle-aged subjects. Diabet Med 21: 39-44.
9. Putz DM, Goldner WS, Bar RS, Haynes WG, Sivitz WI (2004) Adiponectin and C-reactive protein in obesity, type 2 diabetes, and monodrug therapy. Metabolism 53: 1454-1461.
10. Ridker PM, Hennekens CH, Buring JE, Rifai N (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342: 836-843.
11. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347: 1557-1565.
12. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. (2005) C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352: 20-28.
13. Yatagai T, Nagasaka S, Taniguchi A, Fukushima M, Nakamura T, Kuroe A et al. (2003) Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus. Metabolism 52: 1274-1278.
14. Yamamoto Y, Hirose H, Saito I, Tomita M, Taniyama M, Matsubara K, et al. (2002) Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lond) 103: 137-142.
15. Yamamoto Y, Hirose H, Saito I, Nishikai K, Saruta T (2004) Adiponectin, an adipocyte-derived protein, predicts future insulin resistance: two-year follow-up study in Japanese population. J Clin Endocrinol Metab 89: 87-90.
16. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257: 79-83.
17. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20: 1595-1599.
18. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB (2004) Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291: 1730-1737.
19. Maahs DM, Ogden LG, Kinney GL, Wadwa P, Snell-Bergeon JK, Dabelea D, et al. (2005) Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 111: 747-753.
20. Aso Y, Yamamoto R, Wakabayashi S, Uchida T, Takayanagi K, Takebayashi K, et al. (2006) Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes 55: 1954-1960.
21. Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, Ebinuma H, et al. (2006) Measurement of the highmolecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 29: 1357-1362.
22. Basu R, Pajvani UB, Rizza RA, Scherer PE (2007) Selective downregulation of the high-molecular weight form of adiponectin in hyperinsulinemia and in type 2 diabetes-Differential regulation from nondiabetic subjects. Diabetes 56: 2174-2177.
23. Matsubara M, Maruoka S, Katayose S (2002) Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab 87: 2764-2769.
24. Shand BI, Scott RS, Elder PA, George PM (2003) Plasma adiponectin in overweight, nondiabetic individuals with or without insulin resistance. Diabetes Obes Metab 5: 349-353.
25. Krakoff J, Funahashi T, Stehouwer CD, Schalkwijk CG, Tanaka S, Matsuzawa Y, et al. (2003) Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 26: 1745-1751.
26. Engeli S, Feldpausch M, Gorzelniak K, Hartwig F, Heintze U, Janke J, et al. (2003) Association between adiponectin and mediators of inflammation in obese women. Diabetes 52: 942-947.
27. Matsushita K, Yatsuya H, Tamakoshi K, Wada K, Otsuka R, Zhang H, et al. (2006) Inverse association between adiponectin and C-reactive protein in substantially healthy Japanese men. Atherosclerosis 188: 184-189.
28. Schulze MB, Rimm EB, Shai I, Rifai N, Hu FB (2004) Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. Diabetes Care 27: 1680-1687.
29. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A (2004) Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 27: 2450-2457.
30. Mantzoros CS, Li T, Manson JE, Meigs JB, Hu FB (2005) Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes. J Clin Endocrinol Metab 90: 4542-4548.
31. Yuan G, Zhou L, Tang J, Yang Y, Gu W, Li F, et al. (2006) Serum CRP levels are equally elevated in newly diagnosed type 2 diabetes and impaired glucose tolerance and related to adiponectin levels and insulin sensitivity. Diabetes Res Clin Pract 72: 244-250.
32. Van Gaal LF, Mertens IL, De Block CE (2006) Mechanisms linking obesity with cardiovascular disease. Nature 444: 875-880.
33. Behre CJ, Fagerberg B, Hulten LM, Hulthe J (2005) The reciprocal association of adipocytokines with insulin resistance and C-reactive protein in clinically healthy men. Metabolism 54: 439-444.
34. Abbasi F, Farin HM, Lamendola C, McLaughlin T, Schwartz EA, Reaven GM, et al. (2006) The relationship between plasma adiponectin concentration and insulin resistance is altered in smokers. J Clin Endocrinol Metab 91: 5002-5007.
35. Dvorakova-Lorenzova A, Suchanek P, Havel PJ, Stavek P, Karasova L, Valenta Z, et al. (2006) The decrease in C-reactive protein concentration after diet and physical activity induced weight reduction is associated with changes in plasma lipids, but not interleukin-6 or adiponectin. Metabolism 55: 359-365.
36. Timpson NJ, Lawlor DA, Harbord RM, Gaunt TR, Day IN, Palmer LJ, et al. (2005) C-reactive protein and its role in metabolic syndrome: mendelian randomisation study. Lancet 366: 1954-1959.
37. Aronson D, Bartha P, Zinder O, Kerner A, Markiewicz W, Avizohar O, et al. (2004) Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome. Int J Obes Relat Metab Disord 28: 674-679.
38. Kahn SE, Zinman B, Haffner SM, O'Neill MC, Kravitz BG, Yu D, et al. (2006) Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes. Diabetes 55: 2357-2364.
39. Nakano Y, Tajima S, Yoshimi A, Akiyama H, Tsushima M, Tanioka T, et al. (2006) A novel enzymelinked immunosorbent assay specific for high-molecular-weight adiponectin. J Lipid Res 47: 1572-1582.
40. Sakamoto K, Sakamoto T, Ogawa H (2006) Kumamoto Joint Research on Hypercholesterolemia (KOJIROH) Investigators, The effect of 6 months of treatment with pravastatin on serum adiponectin concentrations in Japanese patients with coronary artery disease and hypercholesterolemia: a pilot study. Clin Ther 28: 1012-1021.
41. Hirose H, Kawai T, Yamamoto Y, Taniyama M, Tomita M, Matsubara K, et al. (2002) Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 51: 314-317.
42. Matsushita K, Yatsuya H, Tamakoshi K, Wada K, Otsuka R, Takefuji S, et al. (2006) Comparison of circulating adiponectin and proinflammatory markers regarding their association with metabolic syndrome in Japanese men. Arterioscler Thromb Vasc Biol 26: 871-876.
43. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288: 2709-2716.